Detalhe da pesquisa
1.
Immunogenicity of partial doses of live oral cholera vaccine CVD 103-HgR in children in the United States.
Vaccine
; 41(17): 2739-2742, 2023 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36959054
2.
Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals.
Vaccine
; 41(42): 6146-6149, 2023 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37690874
3.
Update on CVD 103-HgR single-dose, live oral cholera vaccine.
Expert Rev Vaccines
; 21(1): 9-23, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775892
4.
Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.
Lancet Infect Dis
; 22(9): 1343-1355, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35709798
5.
Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States.
Am J Trop Med Hyg
; 104(5): 1758-1760, 2021 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33819178
6.
Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children Aged 2-5 Years in the United States.
Am J Trop Med Hyg
; 104(3): 861-865, 2020 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33319739
7.
Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years.
Am J Trop Med Hyg
; 102(1): 48-57, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769402
8.
Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Clin Infect Dis
; 49(1): e1-10, 2009 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19476428
9.
A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.
Vaccine
; 34(15): 1786-91, 2016 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26928074
10.
Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.
Int J Infect Dis
; 26: 22-30, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24980467
11.
Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.
Hum Vaccin Immunother
; 10(2): 280-9, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24220326
12.
Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.
Vaccine
; 30(26): 3929-36, 2012 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22504039
13.
Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
Pediatr Infect Dis J
; 31(1): 64-71, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22094635
14.
Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
Vaccine
; 28(50): 7865-72, 2010 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-20943209
15.
Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
Clin Vaccine Immunol
; 16(12): 1810-5, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19812260